Cancer cells constantly face a fluctuating nutrient supply and interference with adaptive
responses might be an effective therapeutic approach. It has been discovered that in the …

Although patients with advanced refractory solid tumors have poor prognosis, the clinical
development of targeted protein kinase inhibitors offers hope for the future treatment of many …

Background Mutations in the tumor-suppressor gene VHL cause oversecretion of vascular
endothelial growth factor by clear-cell renal carcinomas. We conducted a clinical trial to …

Purpose New research findings have revealed a key role for vascular endothelial growth
factor (VEGF) in the stimulation of angiogenesis in clear cell renal carcinoma (RCC) which is …

Sunitinib (SU011248) is an oral small molecular tyrosine kinase inhibitor that exhibits potent
antiangiogenic and antitumor activity. Tyrosine kinase inhibitors such as SU6668 and …

BACKGROUND:: Bevacizumab is a recombinant humanized monoclonal antibody that was
approved by the US Food and Drug Administration (FDA) in February 2004 for use as part of …

Purpose To evaluate the efficacy, safety, and pharmacokinetics of multiple doses of CCI-
779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced …

Critical cellular processes are regulated, in part, by maintaining the appropriate intracellular
levels of proteins. Whereas de novo protein synthesis is a comparatively slow process …

Summary von Hippel-Lindau (VHL) tumor suppressor loss results in hypoxia-inducible factor
alpha (HIF-α) stabilization and occurs in 70% of sporadic clear cell renal carcinomas …

Abstract von Hippel-Lindau disease, which is characterized by an increased risk of
hemangioblastomas, clear cell renal carcinomas, and pheochromocytomas, is caused by …